ClinicaliQ Trial Snapshot
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) — Recruiting • Phase III • NCT06338995.
- A drug called lebrikizumab was tested for 18 months to see if it helps patients with nasal polyps who already use nasal steroid sprays.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months. Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Interventions: LY3650150, Placebo, Standard therapy for INCS Lead Sponsor: Eli Lilly and Company Planned Enrollment: 510 participants